Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?
Jeremy W. Jacobs, Laura D. Stephens, David M. Chooljian, Deva Sharma, Brian D. Adkins, Garrett S. Booth
Abstract
The authors declare no conflicts of interest. No new data are reported.
Topics & Concepts
MedicineDiseaseIntensive care medicineFamily medicineInternal medicineHemoglobinopathies and Related DisordersMyeloproliferative Neoplasms: Diagnosis and TreatmentIron Metabolism and Disorders